Scholars@Duke
Bruce Alan Sullenger

Bruce Alan Sullenger

Joseph W. and Dorothy W. Beard Distinguished Professor of Experimental Surgery
Surgery, Surgical Sciences
bruce.sullenger@duke.edu
Box 103035, Durham, NC 27710
DUMC 103035, Durham, NC 27710

Scholarly Works - Conferences

Abstract P102: Elevated Von Willebrand Factor in Patients Presenting With Large-Vessel Occlusion Stroke as First Symptom of COVID-19 Mirrors Levels in Patients With COVID-19 Requiring ICU-Level Care

Conference Stroke · March 2021 Introduction: COVID-19 is a coagulopathic disease marked by elevated d-dimers, fibrinogen, and von Willebrand factor (vWF) levels accompanying arterial and venous thrombosis. While the majority of thr ... Full text Cite

Abstract B006: Development of a novel therapeutic splice-switching oligonucleotide targeting race-related androgen receptor signaling and aggressive prostate cancer

Conference Cancer Epidemiology, Biomarkers & Prevention · June 1, 2020 AbstractBackground: Age-adjusted incidence and mortality rates for prostate cancer (PCa) among African American (AA) men are 1.6- and 2.4-fold greater, respectively, than among white men. The more aggressive ... Full text Cite

Abstract A90: Blocking proinvasive signaling and inflammatory activation in triple-negative breast cancer with nucleic-acid scavengers (NAS)

Conference Cancer Immunology Research · March 1, 2020 AbstractBreast cancers (BC) remain the most lethal malignancies among women worldwide and the second leading cause of cancer-related mortalities in the US. Subtype heterogeneity and aggressive invasive poten ... Full text Cite

Aptamers as Rapid Onset and Rapidly Reversible Antithrombotic Agents

Conference Blood · November 13, 2019 Clinical evaluation of our factor IXa RNA aptamer in two thousand patients undergoing percutaneous coronary intervention has demonstrated that aptamers can rapidly and potently inhibit their target proteins in patients and that antidote molecules c ... Full text Cite

Abstract 4515: Utilizing nucleic-acid scavengers (NASs) to inhibit proinflammatory and proinvasive signaling in triple-negative breast cancer

Conference Cancer Research · July 1, 2019 AbstractBreast cancers (BC) remain the most lethal malignancies amongst women worldwide and the second leading cause of cancer-related mortalities in the US. Subtype heterogeneity and aggressive invasive ... Full text Cite

Targeting DAMPs-Induced Inflammation in Breast Cancer

Conference ANNALS OF SURGICAL ONCOLOGY · February 1, 2019 Link to item Cite

RNA Aptamer Against FXa Synergizes with FXa Catalytic Site Inhibitors to Effectively and Reversibly Anticoagulate Blood in an Ex Vivo Oxygenator Circuit

Conference Blood · December 2, 2016 AbstractDespite notable disadvantages, unfractionated heparin (UFH) remains the standard anticoagulant for clinical procedures requiring potent and reversible anticoagulation such as cardiopulmonary bypass ( ... Full text Cite

Aptamer Mediated Inhibition of Protein S

Conference Blood · December 2, 2016 AbstractProtein S (PS) is an anticoagulant that acts as a direct allosteric inhibitor of the activated form of factor IX (FIXa); FIXa is a coagulant, in both the presence and absence of its cofactor, factor ... Full text Cite

Toll-Like Receptor Signaling as a Prognostic Tool in Trauma Patients

Conference Journal of the American College of Surgeons · October 2016 Full text Cite

Abstract B18: Development of novel therapeutic splice-switching oligonucleotides against aggressive prostate cancer in men of African descent

Conference Cancer Epidemiology, Biomarkers & Prevention · March 1, 2016 AbstractAfrican American (AA) men exhibit a nearly 2-fold higher incidence and 3-fold higher mortality rate from prostate cancer compared to Caucasian American (CA) men and disparities in tumor aggressivenes ... Full text Cite

Development and characterization of an RNA aptamer targeting FV/FVA

Conference JOURNAL OF THROMBOSIS AND HAEMOSTASIS · June 1, 2015 Link to item Cite

AN RNA APTAMER IS A POTENTIAL BIOMARKER FOR PANCREATIC CANCER

Conference NUCLEIC ACID THERAPEUTICS · October 1, 2011 Link to item Cite

Antidote reversal of a novel prothrombin aptamer anticoagulant

Conference JOURNAL OF THROMBOSIS AND HAEMOSTASIS · July 2009 Link to item Cite

Oral delivery of RNA aptamer as reversible antagonist of coagulation factor IXa

Conference ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY · March 22, 2009 Link to item Cite

Blocking Complement-Mediated Hemolysis Using RNA Aptamers That Bind Complement Component C8.

Conference Blood · November 16, 2005 AbstractA recent pilot study in patients with paroxysmal nocturnal hemoglobinuria (PNH), using a humanized monoclonal antibody that binds human complement C5 and inhibits terminal complement protein activati ... Full text Cite

Blocking Complement-Mediated Hemolysis of PNH Erythrocytes by RNA Aptamers to C8 and C9.

Conference Blood · November 16, 2004 AbstractParoxysmal nocturnal hemoglobinuria (PNH) is an acquired hematopoietic stem cell disorder characterized by intravascular hemolysis, venous thrombosis, and bone marrow failure. The lack of GPI-anchore ... Full text Cite